Status: Recruiting
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
This phase I trial studies the best dose and side effects of mesenchymal stromal cells-derived exosomes with KrasG12D siRNA (iExosomes) in treating participants with pancreatic cancer with KrasG12D mutation that has spread to other places in the body. iExosomes may work better at treating pancreatic cancer.
Participants needed: 28
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: M.D. Anderson Cancer CenterUpdated: Sep 4, 2026Locations: 1
Eligibility criteria
Patients with histologically confirmed metastatic pancreatic ductal adenocarcino... [+14]
Concurrent severe and/or uncontrolled medical conditions which could compromise... [+2]